Anti-hyperlipidemic and antioxidant potential of different fractions of Terminalia arjuna Roxb. bark against PX- 407 induced hyperlipidemia.

Department of Pharmacology, PSG College of Pharmacy, Coimbatore 641 004, India.
Indian journal of experimental biology (Impact Factor: 1.2). 04/2011; 49(4):282-8.
Source: PubMed

ABSTRACT The three fractions diethyl ether, ethyl acetate and ethanol. of T. arjuna exerted hypolipidemic and antioxidative effects at two different doses levels of 175 and 350 mg/kg body weight in Poloxamer (PX)-407 induced hyperlipidemic albino Wistar rats. The hypolipidemic and antioxidant effects of T. arjuna fractions were noticed as EtOH > diethyl ether > ethyl acetate. The results suggest that ethanolic fraction of T. arjuna possesses the potent properties of being antioxidant and hypolipidemic than other fractions. In turn, it has therapeutic potential for the prevention of coronary arterial disease.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Terminalia arjuna (Roxb.) Wt. and Arn. is one of the most popular and beneficial medicinal plants in indigenous system of medicine for the treatment of cardiovascular diseases. This comprehensive review provides latest updates on traditional use, phytochemistry, pharmacological and toxicological data, clinical efficacy and safety of T. arjuna as well as outlined strategies for future research and development to scientifically validate the therapeutic potential of this plant.
    Journal of Ethnopharmacology. 01/2014;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To study the antihyperlipidemic effect of Angiosifa, a polyherbal formulation (PHF), in Sprague–Dawley (SD) rats. Methods The rats were divided into seven groups, each having five animals: normal controls, high fat diet (HFD)-fed controls and HFD-fed animals treated with atorvastatin (10 mg/kg), petroleum ether extract of the PHF (200 and 400 mg/kg) and methanol extract of the PHF (200 and 400 mg/kg). The test and standard drugs were administered orally once daily for 28 consecutive days. During the experiment, changes in body weight were noted and alterations in biological and biochemical parameters were monitored at regular intervals. Results HFD-fed animals showed significant increases in body weight and total cholesterol, triglyceride and VLDL levels. They also showed a significant reduction in HDL levels compared with the control and drug treatment groups. Animals treated with atorvastatin and methanol extract of PHF showed significant reductions in total cholesterol, triglyceride and VLDL levels compared with HFD-fed animals. But there was no significant hypolipidemic effect in animals treated with petroleum ether extract of PHF, and the ether caused piloerection and led to cannibalism. Conclusion Methanol extract of PHF has a significant hypolipidemic effect against HFD-induced hyperlipidemia in SD rats. The petroleum ether extract of PHF did not show any significant hypolipidemic effect on HFD-fed rats.
    Pharmacognosy Journal 11/2013; 5(5):221–227.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Terminalia arjuna Wight and Arn. (Combretaceae) is a tree having an extensive medicinal potential in cardiovascular disorders. Triterpenoids are mainly responsible for cardiovascular properties. Aqueous, hydroalcoholic and alcoholic extract of T. arjuna, arjunic acid and arjungenin were examined for their potential to inhibit CYP1A enzyme in rat and human liver microsomes. IC50 values of aqueous, hydroalcoholic and alcoholic extract of T. arjuna was found to be 11.4, 28.9 and 44.6 μg/ml in rat liver microsomes while 30.0, 29.7 and 39.0 μg/ml in human liver microsomes, respectively for CYP1A. However IC50 values of arjunic acid and arjungenin for both rat liver microsomes and human liver microsomes were found to be >50 μM. Arjunic acid and arjungenin did not show inhibition of CYP1A enzyme up to concentrations of 50 μM. These in vitro data indicate that Terminalia arjuna extracts contain constituents that can potently inhibit the activity of CYP1A, which could in turn lead to undesirable pharmacokinetic drug-herb interactions in vivo. Based on the in vitro data, interaction potential of the aqueous extract of Terminalia arjuna orally in rats was investigated. A probe substrate, phenacetin, was used to index the activity of CYP1A. In vivo pharmacokinetic study of coadministration of aqueous extract of Terminalia arjuna and phenacetin, revealed that the aqueous extract did not lead to any significant change in the pharmacokinetic parameters of phenacetin as compared with control group. Though there was no in vivo-in vitro correlation, drug interactions could arise with drugs having a narrow therapeutic range and extensively cleared by CYP1A enzyme, which could lead to undesirable side effects.
    Indian Journal of Pharmaceutical Sciences 03/2014; 76(2):138-47. · 0.34 Impact Factor

Full-text (2 Sources)

Available from
Jun 4, 2014